Selank

Selank: A Research-Use-Only Compound

Selank (Ala-Glu-Thr), also known as 10865-47-9, is a unique research-use-only compound that has garnered attention for its potential in various fields of biological and medical research. This synthetic analog exhibits specific binding to the μ-opioid receptor (MOR) and has been explored extensively in preclinical studies.

Research Context

Selank was first synthesized in 1978 by researchers at the Institute of Chemical Biology, Russian Academy of Sciences. It is part of a class of compound that are structurally and functionally related to endogenous opioids but differ significantly in their receptor binding profiles and pharmacological effects.

Research Overview

The primary focus on Selank has been its interaction with the μ-opioid receptor (MOR) and its potential therapeutic applications. Studies have shown that Selank can modulate various physiological responses, including analgesia, stress reduction, and cognitive enhancement, without causing significant side effects observed in traditional opioids.

Key Research Focus Areas

• Analgesic Effects: Selank has been studied for its ability to provide pain relief through MOR activation. Preclinical studies suggest it may offer a safer alternative to conventional analgesics, especially for chronic pain management.
• Cognitive Enhancement: Research indicates that Selank can improve cognitive functions such as memory and learning in animal models, making it a potential candidate for neuroprotective research.
• Stress Reduction: Studies have shown that Selank may reduce stress levels by modulating the central nervous system’s response to stressors. This could be particularly relevant in the study of anxiety disorders and stress-related pathologies.

Final Compliance Disclaimer

This product is for research use only. Not for human or animal consumption.